CODEMA PHARMA: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
CODEMA PHARMA
Largest movements
- Receivables within one year -€34,665
down €34,665 (-8.5%), from €408,258 to €373,593
of which Other amounts receivable: -€34,665
- Profit (loss) carried forward -€32,963
down €32,963 (-54.3%), from -€60,748 to -€93,711
- Gross operating margin -€25,507
down €25,507 (-284.0%), from -€8,983 to -€34,489
- Financial income +€1,668
new in 2025: €1,668
of which Financial income: +€1,668
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Cash bridge derived
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €409,897 | €375,959 | -€33,938 | -8.3% |
| Current assets | 29/58 | €409,897 | €375,959 | -€33,938 | -8.3% |
| Amounts receivable within one year | 40/41 | €408,258 | €373,593 | -€34,665 | -8.5% |
| Trade receivables | 40 | €47,570 | €47,570 | = | 0.0% |
| Other amounts receivable | 41 | €360,688 | €326,023 | -€34,665 | -9.6% |
| Cash at bank and in hand | 54/58 | €1,639 | €2,366 | +€727 | +44.4% |
| Total equity and liabilities | 10/49 | €409,897 | €375,959 | -€33,938 | -8.3% |
| Equity | 10/15 | €104,252 | €71,289 | -€32,963 | -31.6% |
| Contributions | 10/11 | €165,000 | €165,000 | = | 0.0% |
| Capital | 10 | €165,000 | €165,000 | = | 0.0% |
| Issued capital | 100 | €165,000 | €165,000 | = | 0.0% |
| Profit (loss) carried forward | 14 | -€60,748 | -€93,711 | -€32,963 | -54.3% |
| Amounts payable | 17/49 | €305,645 | €304,670 | -€975 | -0.3% |
| Amounts payable within one year | 42/48 | €303,977 | €304,670 | +€693 | +0.2% |
| Trade debts | 44 | €63,913 | €61,729 | -€2,185 | -3.4% |
| Suppliers | 440/4 | €63,913 | €61,729 | -€2,185 | -3.4% |
| Taxes, remuneration and social security | 45 | €237 | - | -€237 | |
| Taxes | 450/3 | €237 | - | -€237 | |
| Other amounts payable | 47/48 | €239,826 | €242,941 | +€3,115 | +1.3% |
| Accrued charges and deferred income | 492/3 | €1,668 | - | -€1,668 | |
| Gross operating margin | 9900 | -€8,983 | -€34,489 | -€25,507 | -284.0% |
| Operating profit (loss) | 9901 | -€8,983 | -€34,489 | -€25,507 | -284.0% |
| Financial income | 75/76B | - | €1,668 | +€1,668 | |
| Recurring financial income | 75 | - | €1,668 | +€1,668 | |
| Non-recurring financial income | 76B | - | €1,668 | +€1,668 | |
| Financial charges | 65/66B | €248 | €240 | -€9 | -3.5% |
| Recurring financial charges | 65 | €248 | €240 | -€9 | -3.5% |
| Profit (loss) for the period before taxes | 9903 | -€9,231 | -€33,061 | -€23,830 | -258.1% |
| Income taxes | 67/77 | - | -€98 | -€98 | |
| Profit (loss) for the period | 9904 | -€9,231 | -€32,963 | -€23,732 | -257.1% |
| Profit (loss) for the period to be appropriated | 9905 | -€9,231 | -€32,963 | -€23,732 | -257.1% |
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 9 October 2026 via checked.be.